




Daniel James Delitto, MD, PhD, FACS

Assistant Professor of Surgery (General Surgery)
Surgery - General Surgery

 Curriculum Vitae available Online

CLINICAL OFFICE (PRIMARY)

- **Surgical Specialties**

875 Blake Wilbur Dr Rm 2235

MC 5826

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 723-8378

ACADEMIC CONTACT INFORMATION

- **Administrative Contact:**

Kathleen Sochan - Administrative Associate

Email kmsochan@stanford.edu

Tel (650) 497-8822

Bio

BIO

Dr. Delitto is a board certified complex general surgical oncologist with a focus on conditions of the liver, pancreas, and stomach. He is an assistant professor in Stanford Medicine's Department of Surgery.

His education includes a decade of postgraduate training in complex general surgical oncology, as well as a PhD in immunology with an emphasis on cancer biology. He completed a clinical fellowship at Johns Hopkins University and continued his research at the postdoctoral level in the laboratory of Dr. Elizabeth Jaffee. His research focus is on advancing the field of cancer immunology and harnessing his findings to improve immunotherapies.

He was the principal investigator of two studies examining the immune response to pancreatic cancer, including one funded by the National Cancer Institute.

Dr. Delitto has presented the findings of his research at conferences such as the American Association for Cancer Research, Society for the Immunotherapy of Cancer, American Association of Immunologists, American College of Surgeons, Academic Surgical Congress and Pancreas Club. In addition to cancer immunology, he has also presented work focused on cancer cachexia, surgical outcomes, translational experimental models and a variety of other oncologic topics.

He has published original work in Nature Communications, the Journal of the National Cancer Institute, Cancer Research, Clinical Cancer Research, and other high impact journals. He is also a reviewer for Annals of Surgery, Scientific Reports, Surgery, Tumor Biology, Journal of Surgical Research, PLOS ONE, and the Journal of Translational Medicine.

Dr. Delitto has earned numerous honors related to clinical excellence, teaching and research. He is board certified by the American Board of Surgery and a member of the Society of Surgical Oncology, American Association for Cancer Research and American Association of Immunologists.

CLINICAL FOCUS

- General Surgery
- Pancreatic Cancer
- Gastric Cancer
- Bile Duct Cancers
- Gallbladder Cancer
- Sarcoma
- Cancer Immunology

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Surgery - General Surgery
- Member, Bio-X
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- John and Marva Warnock Faculty Scholar, Stanford University School of Medicine

PROFESSIONAL EDUCATION

- Board Certification: Complex General Surgical Oncology, American Board of Surgery (2022)
- Fellowship: Johns Hopkins University Surgery Program (2021) MD
- Residency: University of Florida Dept of General Surgery (2019) FL
- Board Certification: General Surgery, American Board of Surgery (2019)
- PhD Training: University of Florida Office of the Registrar (2016) FL
- Medical Education: University of Pittsburgh School of Medicine Registrar (2011) PA

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Mahsa Fallah

Publications

PUBLICATIONS

- **Distal Pancreatectomy With and Without Celiac Axis Resection for Adenocarcinoma: A Comparison in the Era of Neoadjuvant Therapy**
Daniel, S. K., Hironaka, C., Ahmad, M., Delitto, D., Dua, M., Lee, B., Norton, J., Visser, B., Poultsides, G.
SPRINGER.2024: S202-S203
- **Single cell pharmacogenomic pipeline identifies novel opportunities in uterine leiomyosarcoma**
Daniel, S. K., Foster, D., Nosrati, F., Korah, M., Fallah, M., Sun, B. J., Loftus, T., Hu, D., Dua, M., Visser, B., Poultsides, G., Kirane, A., Longaker, et al
SPRINGER.2024: S42
- **Fibroblasts in the aged pancreas drive pancreatic cancer progression.** *Cancer research*
Zabransky, D. J., Chhabra, Y., Fane, M. E., Kartalia, E., Leatherman, J. M., Hüser, L., Zimmerman, J. W., Delitto, D., Han, S., Armstrong, T. D., Guinn, S., Pramod, S., Thompson, et al
2024

- **Overexpression of Senescence-Associated Genes, SFN and CDC6, Correlates with Poor Survival in Patients with Stage II Hepatocellular Carcinoma (HCC)**
Badshah, J., Subramanian, S., Melcher, M., Sasaki, K., Visser, B., Delitto, D., Pruett, T., Niedernhofer, L., Kirchner, V.
ELSEVIER SCIENCE INC.2024: S64
- **ASO Visual Abstract: Patterns of Recurrence after Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation.** *Annals of surgical oncology*
Hui, C., Ewongwo, A., Lau, B., Fisher, G., Delitto, D., Poultides, G., Ho, Q. A., Rahimy, E., Pollom, E., Chang, D. T., Vitzthum, L. K.
2023
- **Optimized Nuclei Isolation from Fresh and Frozen Solid Tumor Specimens for Multiome Sequencing.** *Journal of visualized experiments : JoVE*
Foster, D. S., Griffin, M., Januszzyk, M., Delitto, D., Norton, J. A., Longaker, M. T.
2023
- **Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma.** *Cell reports. Medicine*
Mascharak, S., Guo, J. L., Foster, D. S., Khan, A., Davitt, M. F., Nguyen, A. T., Burcham, A. R., Chinta, M. S., Guardino, N. J., Griffin, M., Lopez, D. M., Miller, E., Januszzyk, et al
2023: 101248
- **Patterns of Recurrence After Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation.** *Annals of surgical oncology*
Hui, C., Ewongwo, A., Lau, B., Fisher, G., Delitto, D., Poultides, G., Ho, Q., Rahimy, E., Pollom, E., Chang, D. T., Vitzthum, L. K.
2023
- **Mechanoresponsive Pancreatic Ductal Adenocarcinoma Cancer Associated Fibroblasts Shows an FAK-Dependent Subtype Divergent from Canonical Fibrotic TGFB-Pathway Dependence**
Foster, D., Delitto, D., Januszzyk, M., Yost, K., Griffin, M., Guo, J., Guardino, N., Delitto, A., Chinta, M., Burcham, A., Nguyen, A., Bauer-, K., Berry, et al
SPRINGER.2023: S30-S31
- **Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin.** *Cancer cell*
Foster, D. S., Januszzyk, M., Delitto, D., Yost, K. E., Griffin, M., Guo, J., Guardino, N., Delitto, A. E., Chinta, M., Burcham, A. R., Nguyen, A. T., Bauer-Rowe, K. E., Titan, et al
2022
- **Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy.** *World journal of surgery*
Ivey, G. D., Shoucair, S., Delitto, D. J., Habib, J. R., Kinny-Koster, B., Shubert, C. R., Lafaro, K. J., Cameron, J. L., Burns, W. R., Burkhart, R. A., Thompson, E. L., Narang, A., Zheng, et al
2022
- **First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass** *CUREUS JOURNAL OF MEDICAL SCIENCE*
Narayan, R. R., Charville, G. W., Delitto, D., Ganjoo, K. N.
2022; 14 (6)
- **Age-related changes in pancreatic fibroblasts promote growth and progression of pancreatic cancer**
Zabransky, D. J., Chhabra, Y., Fane, M. E., Delitto, D., Zimmermann, J. W., Jaffee, E. M., Weeraratna, A. T.
AMER ASSOC CANCER RESEARCH.2022
- **First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass.** *Cureus*
Narayan, R. R., Charville, G. W., Delitto, D., Ganjoo, K. N.
2022; 14 (6): e26356
- **Surgical solution for a paraneoplastic neurodegenerative disorder.** *Trauma surgery & acute care open*
Muhammad, H., Strayve, D. G., Narayan, R. R., Blayney, D. W., Delitto, D.
2022; 7 (1): e000928
- **Radiographic, Biochemical, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best?**
Javadi, C., Chang, J., Forgo, E., Ahmad, M., Fisher, G. A., Chang, D. T., Delitto, D. J., Dua, M. M., Lee, B., Visser, B. C., Norton, J. A., Poultides, G. A.
SPRINGER.2022: 351
- **Surgical solution for a paraneoplastic neurodegenerative disorder** *TRAUMA SURGERY & ACUTE CARE OPEN*

Muhammad, H., Strayve, D. G., Narayan, R. R., Blayney, D. W., Delitto, D.
2022; 7 (1)

- **Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection.** *Oncoimmunology*
Delitto, D., Zabransky, D. J., Chen, F., Thompson, E. D., Zimmerman, J. W., Armstrong, T. D., Leatherman, J. M., Suri, R., Lopez-Vidal, T. Y., Huff, A. L., Lyman, M. R., Guinn, S. R., Baretta, et al
2021; 10 (1): 2001159
- **GSK3 suppression upregulates β -catenin and c-Myc to abrogate KRas-dependent tumors.** *Nature communications*
Kazi, A., Xiang, S., Yang, H., Delitto, D., Trevino, J., Jiang, R. H., Ayaz, M., Lawrence, H. R., Kennedy, P., Sebt, S. M.
2018; 9 (1): 5154
- **Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy.** *Journal of the National Cancer Institute*
Delitto, D., George, T. J., Loftus, T. J., Qiu, P., Chang, G. J., Allegra, C. J., Hall, W. A., Hughes, S. J., Tan, S. A., Shaw, C. M., Iqbal, A.
2018; 110 (5): 460-466
- **Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment.** *Cancer research*
Delitto, D., Delitto, A. E., DiVita, B. B., Pham, K., Han, S., Hartlage, E. R., Newby, B. N., Gerber, M. H., Behrns, K. E., Moldawer, L. L., Thomas, R. M., George, T. J., Brusko, et al
2017; 77 (3): 672-683
- **Targeting tumor tolerance: A new hope for pancreatic cancer therapy?** *Pharmacology & therapeutics*
Delitto, D., Wallet, S. M., Hughes, S. J.
2016; 166: 9-29